Fidelis Capital Partners LLC Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Fidelis Capital Partners LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 15.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,374 shares of the medical research company’s stock after purchasing an additional 586 shares during the period. Fidelis Capital Partners LLC’s holdings in Edwards Lifesciences were worth $334,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. Moneta Group Investment Advisors LLC grew its position in Edwards Lifesciences by 104,971.3% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the period. Norges Bank acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $658,390,000. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST grew its position in Edwards Lifesciences by 440.0% during the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock worth $243,173,000 after purchasing an additional 2,860,000 shares during the period. AustralianSuper Pty Ltd acquired a new stake in Edwards Lifesciences during the 4th quarter worth about $168,519,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Edwards Lifesciences by 655.9% during the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock worth $173,502,000 after purchasing an additional 2,017,801 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 0.6 %

EW stock opened at $85.94 on Friday. The firm has a market cap of $51.73 billion, a PE ratio of 37.37, a PEG ratio of 4.29 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. The firm’s 50 day moving average price is $90.15 and its 200-day moving average price is $78.31. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.64 earnings per share. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on EW shares. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Morgan Stanley raised their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. Mizuho raised their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Oppenheimer lifted their price objective on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Finally, Wells Fargo & Company upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $91.73.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the transaction, the vice president now owns 173,849 shares in the company, valued at $16,049,739.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 over the last quarter. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.